This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
